Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Authors
Keywords
-
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 33, Issue 3, Pages 710-717
Publisher
Wiley
Online
2017-08-01
DOI
10.1111/jgh.13912
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong
- (2017) Henry Lik-Yuen Chan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals
- (2017) Ming-Lun Yeh et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
- (2017) Jose Luis Calleja et al. JOURNAL OF HEPATOLOGY
- Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
- (2017) Manuel Mendizabal et al. JOURNAL OF MEDICAL VIROLOGY
- Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
- (2017) T. M. Welzel et al. JOURNAL OF VIRAL HEPATITIS
- Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
- (2017) Chen-Hua Liu et al. Open Forum Infectious Diseases
- Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice
- (2016) L. I. Backus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
- (2016) R. Flisiak et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice
- (2016) Esther Chamorro-de-Vega et al. ANNALS OF PHARMACOTHERAPY
- Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
- (2016) George N. Ioannou et al. GASTROENTEROLOGY
- Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1A and GT1B-Infected Patients
- (2016) C. Sarrazin et al. JOURNAL OF HEPATOLOGY
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
- (2016) Jordan J. Feld et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus infection in Taiwan: Past, present, and future
- (2016) Jia-Horng Kao JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
- (2016) C. Perelló et al. JOURNAL OF VIRAL HEPATITIS
- Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin
- (2016) S. Alqahtani et al. JOURNAL OF VIRAL HEPATITIS
- Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
- (2015) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries
- (2015) Masao Omata et al. Hepatology International
- Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping
- (2015) Chen-Hua Liu et al. JOURNAL OF CLINICAL MICROBIOLOGY
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma
- (2014) Mei-Hsuan Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: Asian patients with chronic hepatitis C infection
- (2013) L. H. Nguyen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study
- (2013) Mun Hyuk Seong et al. JOURNAL OF MEDICAL VIROLOGY
- Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
- (2012) Chen-Hua Liu et al. ANTIVIRAL THERAPY
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
- (2011) Chen-Hua Liu et al. ANTIVIRAL THERAPY
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
- (2011) William Sievert et al. LIVER INTERNATIONAL
- Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
- (2008) Chen‐Hua Liu et al. CLINICAL INFECTIOUS DISEASES
- Non-invasive evaluation of liver fibrosis using transient elastography
- (2008) Laurent Castera et al. JOURNAL OF HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now